ALPHARETTA,Inhibitex, a developer of anti-infection medications, has added a veteran pharmaceutical executive to its board of directors.

Keith Willard, former chairman and chief executive officer of Zeneca, was named to the board on Monday. He has also worked with ICI Canada as president and a member of the board.

Inhibitex has five drugs in various stages of development, including one in Phase III clinical trial and another in Phase II.